An agreement between ERT and GE Healthcare has the former integrating the latter's QT Guard Plus Algorithm tool
An agreement between ERT and GE Healthcare has the former integrating the latter's QT Guard Plus Algorithm tool into its centralized cardiac safety EXPERT platform for identifying new drugs that have an effect on QT. The measurement of the QT interval, as required in clinical development for drugs, can be difficult and has led to the termination of promising drugs that showed some degree of QT prolongation in early studies, but otherwise did not demonstrate evidence of proarrhythmia, a harmful effect that can lead to a fatal disordered heartbeat known as Torsades de Pointes (TdP). GE's QT Guard Plus Algorithm identifies and quantifies characteristic changes in the shape of the T-wave found in drugs that produce TdP. The ability to perform this quantitative analysis can help to distinguish between drugs which are proarrhythmic and those which are not.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.